{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T13:23:00Z","timestamp":1778073780262,"version":"3.51.4"},"reference-count":27,"publisher":"Japanese Circulation Society","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Circ Rep"],"published-print":{"date-parts":[[2019,8,9]]},"DOI":"10.1253\/circrep.cr-19-0049","type":"journal-article","created":{"date-parts":[[2019,8,2]],"date-time":"2019-08-02T22:02:59Z","timestamp":1564783379000},"page":"347-351","source":"Crossref","is-referenced-by-count":7,"title":["Rationale and Design of the CANONICAL Study\u3000\u2015 Randomized, Open-Label Study to Evaluate the Efficacy and Safety of Canagliflozin for Heart Failure With Preserved Ejection Fraction With Type 2 Diabetes Mellitus \u2015"],"prefix":"10.1253","volume":"1","author":[{"given":"Shu","family":"Kasama","sequence":"first","affiliation":[{"name":"Nara Medical University Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tohru","family":"Masuyama","sequence":"additional","affiliation":[{"name":"Hyogo College of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shiro","family":"Uemura","sequence":"additional","affiliation":[{"name":"Kawasaki Medical School"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yukihito","family":"Sato","sequence":"additional","affiliation":[{"name":"Hyogo Prefectural Amagasaki General Medical Center"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinya","family":"Hiramitsu","sequence":"additional","affiliation":[{"name":"Hiramitsu Heart Clinic"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Izuru","family":"Masuda","sequence":"additional","affiliation":[{"name":"Takeda Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuhiro","family":"Yamamoto","sequence":"additional","affiliation":[{"name":"Tottori University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sei","family":"Komatsu","sequence":"additional","affiliation":[{"name":"Osaka Gyoumeikan Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshihisa","family":"Anzai","sequence":"additional","affiliation":[{"name":"Hokkaido University Graduate School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kunihiro","family":"Nishimura","sequence":"additional","affiliation":[{"name":"National Cerebral and Cardiovascular Center"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomoya","family":"Ueda","sequence":"additional","affiliation":[{"name":"Nara Medical University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masato","family":"Kasahara","sequence":"additional","affiliation":[{"name":"Nara Medical University Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroyuki","family":"Tanaka","sequence":"additional","affiliation":[{"name":"Mitsubishi Tanabe Pharma Corporation"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yutaka","family":"Susuta","sequence":"additional","affiliation":[{"name":"Mitsubishi Tanabe Pharma Corporation"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshihiko","family":"Saito","sequence":"additional","affiliation":[{"name":"Nara Medical University"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"330","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Ambrosy AP, Fonarow GC, Butler J, Chioncel O, Greene SJ, Vaduganathan M, et al. The global health and economic burden of hospitalizations for heart failure: Lessons learned from hospitalized heart failure registries. <i>J Am Coll Cardiol<\/i> 2014; 63: 1123\u20131133.","DOI":"10.1016\/j.jacc.2013.11.053"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Sakata Y, Shimokawa H. Epidemiology of heart failure in Asia. <i>Circ J<\/i> 2013; 77: 2209\u20132217.","DOI":"10.1253\/circj.CJ-13-0971"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Yamamoto K, Sakata Y, Ohtani T, Takeda Y, Mano T. Heart failure with preserved ejection fraction. <i>Circ J<\/i> 2009; 73: 404\u2013410.","DOI":"10.1253\/circj.CJ-08-1073"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Goodlin SJ. Palliative care in congestive heart failure. <i>J Am Coll Cardiol<\/i> 2009; 54: 386\u2013396.","DOI":"10.1016\/j.jacc.2009.02.078"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Nagai T, Yoshikawa T, Saito Y, Takeishi Y, Yamamoto K, Ogawa H, et al. Clinical characteristics, management, and outcomes of Japanese patients hospitalized for heart failure with preserved ejection fraction: A report from the Japanese Heart Failure Syndrome With Preserved Ejection Fraction (JASPER) Registry. <i>Circ J<\/i> 2018; 82: 1534\u20131545.","DOI":"10.1253\/circj.CJ-18-0073"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. <i>N Engl J Med<\/i> 2015; 373: 2117\u20132128.","DOI":"10.1056\/NEJMoa1504720"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Neal B, Perkovic V, Mahaffey KW, de Zeeuw D, Fulcher G, Erondu N, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. <i>N Engl J Med<\/i> 2017; 377: 644\u2013657.","DOI":"10.1056\/NEJMoa1611925"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Wiviott SD, Raz I, Bonaca MP, Mosenzon O, Kato ET, Cahn A, et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. <i>N Engl J Med<\/i> 2019; 380: 347\u2013357.","DOI":"10.1056\/NEJMoa1812389"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Kosiborod M, Lam CSP, Kohsaka S, Kim DJ, Karasik A, Shaw J, et al. Cardiovascular events associated with SGLT-2 inhibitors versus other glucose-lowering drugs: The CVD-REAL 2 Study. <i>J Am Coll Cardiol<\/i> 2018; 71: 2628\u20132639.","DOI":"10.1016\/j.jacc.2018.03.009"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Davies MJ, D\u2019Alessio DA, Fradkin J, Kernan WN, Mathieu C, Mingrone G, et al. Management of hyperglycemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). <i>Diabetes Care<\/i> 2018; 41: 2669\u20132701.","DOI":"10.2337\/dci18-0033"},{"key":"11","unstructured":"11. The Japan Diabetes Society. Treatment guide for diabetes 2018\u20132019. Tokyo: Bunkodo, 2018."},{"key":"12","unstructured":"12. Guidelines for diagnosis and treatment of acute and chronic heart failure (JCS 2017\/JHFS 2017) (in Japanese). http:\/\/www.j-circ.or.jp\/guideline\/pdf\/JCS2017_tsutsui_h.pdf (accessed December 10, 2018)."},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Inagaki N, Kondo K, Yoshinari T, Takahashi N, Susuta Y, Kuki H. Efficacy and safety of canagliflozin monotherapy in Japanese patients with type 2 diabetes inadequately controlled with diet and exercise: A 24-week, randomized, double-blind, placebo-controlled, phase III study. <i>Expert Opin Pharmacother<\/i> 2014; 15: 1501\u20131515.","DOI":"10.1517\/14656566.2014.935764"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Kadowaki T, Kondo K. Efficacy, safety and dose-response relationship of teneligliptin, a dipeptidyl peptidase-4 inhibitor, in Japanese patients with type 2 diabetes mellitus. <i>Diabetes Obes Metab<\/i> 2013; 15: 810\u2013818.","DOI":"10.1111\/dom.12092"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Kadowaki T, Kondo K. Efficacy and safety of teneligliptin in combination with pioglitazone in Japanese patients with type 2 diabetes mellitus. <i>J Diabetes Investig<\/i> 2013; 4: 576\u2013584.","DOI":"10.1111\/jdi.12092"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Kadowaki T, Marubayashi F, Yokota S, Katoh M, Iijima H. Safety and efficacy of teneligliptin in Japanese patients with type 2 diabetes mellitus: A pooled analysis of two phase III clinical studies. <i>Expert Opin Pharmacother<\/i> 2015; 16: 971\u2013981.","DOI":"10.1517\/14656566.2015.1032249"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Li L, Li S, Liu J, Deng K, Busse JW, Vandvik PO, et al. Glucagon-like peptide-1 receptor agonists and heart failure in type 2 diabetes: Systematic review and meta-analysis of randomized and observational studies. <i>BMC Cardiovasc Disord<\/i> 2016; 16: 91.","DOI":"10.1186\/s12872-016-0260-0"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Green JB, Bethel MA, Armstrong PW, Buse JB, Engel SS, Garg J, et al. Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. <i>N Engl J Med<\/i> 2015; 373: 232\u2013242.","DOI":"10.1056\/NEJMoa1501352"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Scirica BM, Bhatt DL, Braunwald E, Steg PG, Davidson J, Hirshberg B, et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. <i>N Engl J Med<\/i> 2013; 369: 1317\u20131326.","DOI":"10.1056\/NEJMoa1307684"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. White WB, Cannon CP, Heller SR, Nissen SE, Bergenstal RM, Bakris GL, et al. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. <i>N Engl J Med<\/i> 2013; 369: 1327\u20131335.","DOI":"10.1056\/NEJMoa1305889"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Iijima H, Kifuji T, Maruyama N, Inagaki N. Pharmacokinetics, pharmacodynamics, and safety of canagliflozin in Japanese patients with type 2 diabetes mellitus. <i>Adv Ther<\/i> 2015; 32: 768\u2013782.","DOI":"10.1007\/s12325-015-0234-0"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Tanaka H, Takano K, Iijima H, Kubo H, Maruyama N, Hashimoto T, et al. Factors affecting canagliflozin-induced transient urine volume increase in patients with type 2 diabetes mellitus. <i>Adv Ther<\/i> 2017; 34: 436\u2013451.","DOI":"10.1007\/s12325-016-0457-8"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Hallow KM, Helmlinger G, Greasley PJ, McMurray JJV, Boulton DW. Why do SGLT2 inhibitors reduce heart failure hospitalization?: A differential volume regulation hypothesis. <i>Diabetes Obes Metab<\/i> 2018; 20: 479\u2013487.","DOI":"10.1111\/dom.13126"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. Tikkanen I, Narko K, Zeller C, Green A, Salsali A, Broedl UC, et al. Empagliflozin reduces blood pressure in patients with type 2 diabetes and hypertension. <i>Diabetes Care<\/i> 2015; 38: 420\u2013428.","DOI":"10.2337\/dc14-1096"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25. Chaudhry SI, Wang Y, Concato J, Gill TM, Krumholz HM. Patterns of weight change preceding hospitalization for heart failure. <i>Circulation<\/i> 2007; 116: 1549\u20131554.","DOI":"10.1161\/CIRCULATIONAHA.107.690768"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26. Sha S, Polidori D, Heise T, Natarajan J, Farrell K, Wang SS, et al. Effect of the sodium glucose co-transporter 2 inhibitor canagliflozin on plasma volume in patients with type 2 diabetes mellitus. <i>Diabetes Obes Metab<\/i> 2014; 16: 1087\u20131095.","DOI":"10.1111\/dom.12322"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27. Kambara T, Shibata R, Osanai H, Nakashima Y, Asano H, Sakai K, et al. Use of sodium-glucose cotransporter 2 inhibitors in older patients with type 2 diabetes mellitus. <i>Geriatr Gerontol Int<\/i> 2018; 18: 108\u2013114.","DOI":"10.1111\/ggi.13149"}],"container-title":["Circulation Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/circrep\/1\/8\/1_CR-19-0049\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,8,10]],"date-time":"2019-08-10T03:19:10Z","timestamp":1565407150000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/circrep\/1\/8\/1_CR-19-0049\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8,9]]},"references-count":27,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2019]]}},"URL":"https:\/\/doi.org\/10.1253\/circrep.cr-19-0049","relation":{},"ISSN":["2434-0790"],"issn-type":[{"value":"2434-0790","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,8,9]]}}}